轻型卒中患者的溶栓治疗进展

doi:10.3969/j.issn.1673-5765.2021.10.017

摘要/Abstract

摘要： 轻型卒中的定义及标准目前尚未统一，其是否需要溶栓是卒中领域尚未解决的问题之一。轻型卒中在卒中患者中的比例较大且有上升趋势，并且增加致残和复发的风险。轻型卒中患者即便在 4.5 h内到达医院也常因症状较轻而未能接受溶栓治疗，而这些未溶栓患者中有29%预后不良。轻型卒中患者溶栓治疗的有效性及安全性均存在很大争议，而溶栓治疗的时间窗、卒中是否致残、NIHSS 评分、病因学分型等因素均可影响其预后，需要更多的研究来评估溶栓治疗对轻型卒中患者的意义。

文章导读： 轻型卒中患者比例很大且预后不佳，目前研究对轻型卒中患者溶栓治疗的有效性及安全性均存在很大争议，期待进一步高质量的研究为临床实践提供更多依据。

关键词: 轻型卒中; 溶栓治疗; 阿替普酶; 预后; 影响因素

Abstract: Whether mild stroke patients should receive thrombolytic therapy remains an unresolved problem. The definition and standard for mild stroke are not unified till now. Mild stroke accounts for a large proportion in stroke and has an increasing trend at home and abroad. It increased the risk of disability and stroke recurrence. Patients with mild stroke often fail to receive intravenous thrombolysis even if they arrive at the hospital within the 4.5-hour time window, and 29% of these patients without thrombolysis have a poor outcome. The safety and efficacy of thrombolytic therapy in patients with mild stroke are controversial. The time window, disability or not, NIHSS score, etiological type and other factors all can affect the prognosis. More studies are needed to evaluate the significance of thrombolytic therapy in patients with mild stroke.

Key words: Mild stroke; Thrombolytic therapy; Alteplase; Prognosis; Predictor

闫然, 熊云云, 李子孝. 轻型卒中患者的溶栓治疗进展[J]. 中国卒中杂志, 2021, 16(10): 1075-1081.

YAN Ran, XIONG Yun-Yun, LI Zi-Xiao. Advances in Intravenous Thrombolysis for Mild Stroke Patients[J]. Chinese Journal of Stroke, 2021, 16(10): 1075-1081.

参考文献

[1] WANG Y J，LI Z X，GU H Q，et al. China stroke
statistics 2019：a report from the National Center
for Healthcare Quality Management in Neurological
Diseases，China National Clinical Research Center
for Neurological Diseases，the Chinese Stroke
Association，National Center for Chronic and Noncommunicable
Disease Control and Prevention，
Chinese Center for Disease Control and Prevention
and Institute for Global Neuroscience and Stroke
Collaborations[J]. Stroke Vasc Neurol，2020，5（3）：
211-239.
[2] WANG Y J，LI Z X，WANG Y L，et al. Chinese
Stroke Center Alliance：a national effort to improve
healthcare quality for acute stroke and transient
ischaemic attack：rationale，design and preliminary
findings[J]. Stroke Vasc Neurol，2018，3（4）：256-
262.
[3] TAN Y，PAN Y S，LIU L P，et al. One-year
outcomes and secondary prevention in patients after
acute minor stroke：results from the China national
stroke registry[J]. Neurol Res，2017，39（6）：484-
491.
[4] KHATRI P，CONAWAY M R，JOHNSTON K C，et
al. Ninety-day outcome rates of a prospective cohort
of consecutive patients with mild ischemic stroke[J].
Stroke，2012，43（2）：560-562.
[5] ASDAGHI N，WANG K，CILIBERTI-VARGAS M
A，et al. Predictors of thrombolysis administration
in mild stroke：florida-puerto rico collaboration to
reduce stroke disparities[J]. Stroke，2018，49（3）：
638-645.
[6] ROMANO J G，SMITH E E，LIANG L，et al.
Outcomes in mild acute ischemic stroke treated with
intravenous thrombolysis：a retrospective analysis of
the get with the guidelines-stroke registry[J]. JAMA
Neurol，2015，72（4）：423-431.
[7] CUCCHIARA B，GEORGE D K，KASNER S
E，et al. Disability after minor stroke and TIA：a
secondary analysis of the SOCRATES trial[J/OL].
Neurology，2019，93（7）：e708-e716[2021-03-10].
https：//doi.org/10.1212/WNL.0000000000007936.
[8] HURFORD R，LI L X，LOVETT N，et al.
Prognostic value of "tissue-based" definitions of TIA
and minor stroke：population-based study[J/OL].
Neurology，2019，92（21）：e2455-e2461[2021-03-10].
https：//doi.org/10.1212/WNL.0000000000007531.
[9] WILLEY J Z，KHATRI P，KHOURY J C，et al.
Variability in the use of intravenous thrombolysis

for mild stroke：experience across the SPOTRIAS

network[J]. J Stroke Cerebrovasc Dis，2013，22（4）：
318-322.
[10] KAMEL H，ZHANG C N，KLEINDORFER D O，
et al. Association of black race with early recurrence
after minor ischemic stroke or transient ischemic
attack：secondary analysis of the POINT randomized
clinical trial[J]. JAMA Neurol，2020，77（5）：601-
605.
[11] XIONG Y Y，GU H Q，ZHAO X Q，et al. Clinical
characteristics and in-hospital outcomes of varying
definitions of minor stroke：from a large-scale
nation-wide longitudinal registry[J]. Stroke，2021，52
（4）：1253-1258.
[12] MAJIDI S，LUBY M，LYNCH J K，et al. MRIbased
thrombolytic therapy in patients with acute
ischemic stroke presenting with a low NIHSS[J/OL].
Neurology，2019，93（16）：e1507-e1513[2021-03-10].
https：//doi.org/10.1212/WNL.0000000000008312.
[13] LI Z X，WANG C J，ZHAO X Q，et al. Substantial
progress yet significant opportunity for improvement
in stroke care in China[J]. Stroke，2016，47（11）：
2843-2849.
[14] REEVES M，KHOURY J，ALWELL K，et al.
Distribution of National Institutes of Health stroke
scale in the Cincinnati/Northern Kentucky stroke
study[J]. Stroke，2013，44（11）：3211-3213.
[15] AMARENCO P，LAVALLÉE P C，LABREUCHE J，
et al. One-year risk of stroke after transient ischemic
attack or minor stroke[J]. N Engl J Med，2016，374
（16）：1533-1542.
[16] JU Y，ZHAO X Q，WANG C X，et al. Neurological
deterioration in the acute phase of minor ischemic
stroke is an independent predictor of poor outcomes
at 1 year：results from the China national stroke
registry（CNSR）[J]. Chin Med J（Engl），2013，126
（18）：3411-3416.
[17] National Institute of Neurological Disorders Stroke
rt-PA Stroke Study Group. Recombinant tissue
plasminogen activator for minor strokes：the
National Institute of Neurological Disorders and
Stroke rt-PA stroke study experience[J]. Ann Emerg
Med，2005，46（3）：243-252.
[18] EMBERSON J，LEES K R，LYDEN P，et al. Effect
of treatment delay，age，and stroke severity on the
effects of intravenous thrombolysis with alteplase for
acute ischaemic stroke：a meta-analysis of individual
patient data from randomised trials[J]. Lancet，2014，
384（9958）：1929-1935.
[19] CHOI J C，JANG M U，KANG K，et al.
Comparative effectiveness of standard care with
Ⅳ thrombolysis versus without Ⅳ thrombolysis for
mild ischemic stroke[J/OL]. J Am Heart Assoc，2015，
4（1）：e001306[2021-03-10]. https：//doi.org/10.
1161/JAHA.114.000596.
[20] KHATRI P，TAYAMA D，COHEN G，et al. Effect
of intravenous recombinant tissue-type plasminogen
activator in patients with mild stroke in the third
international stroke trial-3：post hoc analysis[J].
Stroke，2015，46（8）：2325-2327.
[21] KHATRI P，KLEINDORFER D O，YEATTS S D，
et al. Strokes with minor symptoms：an exploratory
analysis of the National Institute of Neurological
Disorders and Stroke recombinant tissue
plasminogen activator trials[J]. Stroke，2010，41（11）：
2581-2586.
[22] KHATRI P，KLEINDORFER D O，DEVLIN T，
et al. Effect of alteplase vs aspirin on functional
outcome for patients with acute ischemic stroke and
minor nondisabling neurologic deficits：the PRISMS
randomized clinical trial[J]. JAMA，2018，320（2）：
156-166.
[23] POWERS W J，RABINSTEIN A A，ACKERSON
T，et al. Guidelines for the early management of
patients with acute ischemic stroke：2019 update
to the 2018 guidelines for the early management of
acute ischemic stroke：a guideline for healthcare
professionals from the American Heart Association/
American Stroke Association[J/OL]. Stroke，2019，
50（12）：e344-e418[2021-03-10]. https：//doi.org/10.
1161/STR.0000000000000211.
[24] BERGE E，WHITELEY W，AUDEBERT
H，et al. European Stroke Organisation（ESO）
guidelines on intravenous thrombolysis for acute
ischaemic stroke[J/OL]. Eur Stroke J，2021，6
（1）：Ⅰ-LⅫ[2021-03-10]. https：//doi.org/10.
1177/2396987321989865.
[25] PARSONS M，SPRATT N，BIVARD A，et al. A
randomized trial of tenecteplase versus alteplase for
acute ischemic stroke[J]. N Engl J Med，2012，366
（12）：1099-1107.
[26] RØNNING O M，LOGALLO N，THOMMESSEN
B，et al. Tenecteplase versus alteplase between 3 and
4.5 hours in low National Institutes of Health stroke
scale[J]. Stroke，2019，50（2）：498-500.
[27] AHMED N，WAHLGREN N，GROND M，et al.
Implementation and outcome of thrombolysis with
alteplase 3-4.5 h after an acute stroke：an updated
analysis from SITS-ISTR[J]. Lancet Neurol，2010，9
（9）：866-874.
[28] TSIVGOULIS G，GOYAL N，KATSANOS A H，et
al. Intravenous thrombolysis for large vessel or distal
occlusions presenting with mild stroke severity[J].
Eur J Neurol，2020，27（6）：1039-1047.
[29] TURC G，BHOGAL P，FISCHER U，et al. European
Stroke Organisation（ESO）- European Society for
Minimally Invasive Neurological Therapy（ESMINT）
guidelines on mechanical thrombectomy in acute
ischemic stroke[J]. J Neurointerv Surg，2019，11（6）：
535-538.
[30] LEIRA E C，LUDWIG B R，GUROL M E，et al.
The types of neurological deficits might not justify
withholding treatment in patients with low total
National Institutes of Health stroke scale scores[J].
Stroke，2012，43（3）：782-786.
[31] ESKIOGLOU E，HUCHMANDZADEH
MILLOTTE M，AMIGUET M，et al. National
Institutes of Health stroke scale zero strokes[J].
Stroke，2018，49（12）：3057-3059.
[32] XIN X Y，CHENG L，YANG Z，et al. Comparison
study of ASCO and TOAST classification system in
Chinese minor stroke patients[J]. Cerebrovasc Dis，
2019，47（1/2）：95-100.
[33] CHEN W Q，PAN Y S，ZHAO X Q，et al.
Intravenous thrombolysis in Chinese patients with
different subtype of mild stroke：thrombolysis in
patients with mild stroke[J]. Sci Rep，2017，7（1）：
2299.
[34] WANG D P，ZHANG L L，HU X W，et al.
Intravenous thrombolysis benefits mild stroke
patients with large-artery atherosclerosis but no
tandem steno-occlusion[J/OL]. Front Neurol，2020，
11：340[2021-03-10]. https：//doi.org/10.3389/fneur.
2020.00340.
[35] 王伊龙，赵性泉，刘新峰，等. 高危非致残性缺血
性脑血管事件诊疗指南[J]. 中国卒中杂志，2016，11
（6）：481-491.
[36] WU L Y，WANG A X，WANG X W，et al. Factors
for short-term outcomes in patients with a minor
stroke：results from China national stroke registry[J/
OL]. BMC Neurol，2015，15：253[2021-03-10]. https：
//doi.org/10.1186/s12883-015-0505-z.
[37] CUCCHIARA B，ELM J，EASTON J D，et al.
Disability after minor stroke and transient ischemic
attack in the POINT trial[J]. Stroke，2020，51（3）：
792-799.